Phase I Trial of a Genetically Engineered Interleukin-2 Fusion Toxin (DAB₄₈₆IL-2) as a 6 Hour Intravenous Infusion in Patients with Hematologic Malignancies

References

• Pastan I., Fitzgerald D. Recombinant toxins for cancer treatment. Science 1991; 254: 1173–77
   PubMed Web of Science ®Google Scholar
• Waters C. A., Schimke P. A., Snider C. E., Snider C. E., Itoh K., Smith K. A., Nichols J. C., Strom T. B., Murphy J. R. Interleukin-2 receptor targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin-2 fusion protein into cells. Eur. J. Immunol. 1990; 20: 785–91
   PubMed Web of Science ®Google Scholar
• Williams D., Parker K., Bacha P., Bishai W., Genbauffe F., Strom T. B., Murphy J. R. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1987; 1: 493–98
   PubMedGoogle Scholar
• Bacha P., Williams D. P., Waters C., Williams J. M., Murphy J. R., Strom T. B. Interleukin-2 receptor targeted cytotoxicity: interleukin-2 receptor-mediated action of diphtheria toxin-related interleukin-2 fusion protein. J. Exp. Med. 1988; 167: 612–22
   PubMed Web of Science ®Google Scholar
• Le Maistre C. F., Meneghetti C., Rosenblum M., Reuben J., Shaw J., Deisseroth A., Woodworth T., Parkinson D. P. Phase I trial of an IL-2 fusion toxin (DAB486L-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79: 55–58
   Google Scholar
• Waldmann T. A. The multi-subunit IL-2 receptor. Ann. Rev. Biochem. 1988; 58: 875–911
   Web of Science ®Google Scholar
• Waldmann T. A. Multichain interleukin-2 receptor: A target for immunotherapy in lymphoma. J. Natl. Cancer Inst. 1989; 81: 914–23
   PubMed Web of Science ®Google Scholar
• Allouche M., Saahraoui Y., Augrey-Bourget Y., Ohashi Y., Sugamura K., Jasmin C., Georgulias V. Presence of p70 IL-2 binding peptide on leukemic cells from various hemopoietic lineages. J. Immunol. 1989; 143: 2223–28
   PubMed Web of Science ®Google Scholar
• Bentaboulet M., Allouche M., Tsapis A., Jasmin C., Georgoulias V. Characterization of interleukin-2 receptors expressed on acute leukemic B-cells. Blood 1987; 70: 954–959
   PubMed Web of Science ®Google Scholar
• Casey T. T., Olsen S. J., Cousar J. B., Collins R. D. Immunophenotype of Reed-Sternberg cells: A study of 19 cases of Hodgkin's disease in plastic-unbedded sections. Blood 1988; 74: 2624–28
   Google Scholar
• Delsol G., Al Saati T., Gatter C. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large-cell lymphomas. Am. J. Pathol. 1988; 130: 59–70
   PubMed Web of Science ®Google Scholar
• Grant B. W., Piatt J. L., Jacob H. S., Kay N. E. Lymphocyte populations and Tac-antigen in diffuse B-cell lymphomas. Leuk. Res. 1986; 10: 1271–78
   PubMed Web of Science ®Google Scholar
• Ichikawa M., Kawai H., Komiyama A., Tsudo M., Miyasaka M., Kinoshita A., Nakazawa S. Functional p75 interleukin-2 receptor expression on the fresh blast cells in childhood acute lymphoblastic leukemia with natural killer cell properties. Am. J. Hematol. 1991; 36: 259–64
   PubMed Web of Science ®Google Scholar
• Korsmeyer S. J., Greene W. C., Cossman J., Hsu S. M., Jensen J. P., Neckers L. M., Marshall S. L., Bakhshi A., Depper J. M., Leonard W. J., Jaffe E. S., Waldmann T. A. Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc. Natl. Acad. Sci. USA 1983; 80: 4522–26
   PubMed Web of Science ®Google Scholar
• Nakase K., Kita K., Otsuji A., Anazawa H., Hoshino K., Sekine T., Shirakawa S., Tanaka I., Nasu K., Tsutani H., Dohy H., Tsudo M. Diagnostic and clinical importance of interleukin-2 receptor alpha chain expression on non-T-cell acute leukemia cells. Br. J. Haematol. 1992; 80: 317–26
   PubMed Web of Science ®Google Scholar
• Rosolen A., Nakanishi M., Poplack D., Cole D., Quinones R., Reaman G., Cotelingan J. D., Trepel J. B., Sausville E., Marti G. E., Neckers L. M., Colamonici O. R. Expression of interleukin-2 receptor β subunit in hematologic malignancies. Blood 1989; 73: 1968–72
   PubMed Web of Science ®Google Scholar
• Schwarting R., Gerdes J., Stein H. Expression of interleukin-2 receptor on Hodgkin's and non-Hodgkin's lymphoma and macrophages. J. Clin. Pathol. 1985; 38: 1196–97
   PubMed Web of Science ®Google Scholar
• Strauchen J. A., Breakstone B. A. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am. J. Pathol. 1987; 126: 506–12
   PubMed Web of Science ®Google Scholar
• Touw I., Lowenberg B. Interleukin-2 stimulates chronic lymphocytic leukemia colony formation in vitro. Blood 1985; 66: 237–240
   PubMed Web of Science ®Google Scholar
• Touw I., Dorsser L., Lowenbeg B. The proliferative response of B cell chronic lymphocytic leukemia to interleukin-2: Functional characterization of the interleukin 2 membrane receptors. Blood 1987; 69: 1667–73
   PubMed Web of Science ®Google Scholar
• Yagura T., Tamaki T., Furitsu T., Tominaga N., Katagiri S., Yonezawa T., Tarui S. Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: Functional and structural characterization. Blut 1990; 60: 181–186
   PubMedGoogle Scholar
• Uchiyama T., Hori T., Tsudo M., Wano Y., Umadome H., Tamori S., Maeda H., Sawami H., Uchino H. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J. Clin. Invest. 1985; 76: 446–53
   PubMed Web of Science ®Google Scholar
• Kuzel T., Rosen S., Gordon L., Winter J., Samuelson E., Kaul K., Roegnick H., Nylen P., Woodworm T. Safety and biologic effects of DAB486 IL-2 in IL-2 receptor expressing malignancies. Proc. Am. Assoc. Cancer Res. 1992; 32: 227
   Google Scholar
• Schwartz G., Tepler I., Charette J., Kadin M., Parker K., Woodworth T., Schnipper L. Complete response of a Hodgkin's lymphoma in a phase I trial of DAB486 IL-2, an IL-2 diphtheria fusion toxin. Blood 1991; 78(Suppl. 1)175
   PubMedGoogle Scholar
• Le Maistre C. F., Craig F. E., Meneghetti C., McMullin B., Parker K., Reuben J., Boldt D. H., Rosenblum M., Woodworth T. Phase I trial of a 90 minute infusion of the fusion toxin DAB486 IL-2 in hematological cancers. Cancer Res. 1993; 53: 3930–34
   PubMed Web of Science ®Google Scholar
• Hesketh P., Caguioa P., Koh H., Dewey H., Facada A., McCaffrey R., Parker K., Nylen P., Woodworth T. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 1993; 9: 1682–90
   Google Scholar